INDIANAPOLIS, Indiana: Eli Lilly surged into a rarefied tier of corporate giants on November 21, becoming the first pharmaceutical company in history to reach a US$1 trillion market valuation, a milestone driven almost entirely by the explosive global demand for new obesity and diabetes drugs.

The company's stock, up more than 35 percent this year, briefly touched a record high and traded nearly one percent firmer at $1,051. Lilly's rapid ascent reflects how the weight-loss drug market has transformed from a niche category into one of the most lucrative areas in healthcare.

In just two years, highly effective obesity treatments have redrawn the competitive landscape. Sales of Lilly's tirzepatide—marketed as Mounjaro for diabetes and Zepbound for obesity—have overtaken Merck's Keytruda to become the world's best-selling drug. While Novo Nordisk initially led the market with Wegovy, Lilly has pulled ahead in prescriptions, helped by Wegovy's early supply shortages and the stronger clinical efficacy of tirzepatide.

Lilly has also been quicker to expand manufacturing and distribution, allowing it to meet surging demand. Since the launch of Zepbound in late 2023, the company's shares have climbed more than 75 percent, far outpacing the S&P 500's roughly 50 percent gain in the same period.

The market now values Lilly at roughly 50 times its expected earnings over the next year, according to LSEG data—one of the richest valuations in global pharma and a signal of investor conviction that the weight-loss drug boom has years to run.

In its latest quarterly report, Lilly posted more than $10.09 billion in combined revenue from its obesity and diabetes portfolio, accounting for over half of its total $17.6 billion in sales. "The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise," said Evan Seigerman of BMO Capital Markets.

Analysts expect the global weight-loss drug market to reach $150 billion by 2030, with Lilly and Novo Nordisk accounting for the bulk of sales.

Much of the near-term focus now is on Lilly's following major product: its oral obesity drug, orforglipron, expected to be approved early next year. Citi analysts described GLP-1 treatments as a "sales phenomenon" and said orforglipron stands to benefit from the momentum created by its injectable predecessors.

Lilly also stands to gain from a pricing deal with the Trump administration, even if it compresses revenue in the short term. Analysts say the agreement could dramatically expand access, adding as many as 40 million potential U.S. candidates for obesity treatment.

The company's meteoric rise is drawing comparisons to the tech-sector "Magnificent Seven." "Lilly is starting to resemble the ‘Magnificent Seven' again," said James Shin of Deutsche Bank, noting its renewed appeal to investors at a time when some AI-focused stocks are facing volatility.

Still, questions remain about whether Lilly can maintain its growth pace as pricing pressure intensifies and whether its manufacturing scale-up and broader drug pipeline can offset a potential margin squeeze.